{
  "analysis": "Strategy A - Orthogonal Survival Validation",
  "cohort": "TCGA-OV TRUE-SAE v2",
  "n_patients": 161,
  "log_rank": {
    "test_statistic": 6.134,
    "p_value": 0.013259,
    "significant_005": true
  },
  "cox": {
    "hazard_ratio": 0.615,
    "ci_lower": 0.42,
    "ci_upper": 0.9,
    "p_value": 0.014177,
    "interpretation": "HR < 1 means HIGH DDR_bin = LOWER death risk = LONGER survival"
  },
  "kaplan_meier": {
    "median_os_high_months": 68.9,
    "median_os_low_months": 51.0,
    "difference_months": 17.9,
    "n_high": 80,
    "n_low": 81,
    "events_high": 49,
    "events_low": 56
  },
  "conclusion": "ORTHOGONAL VALIDATION PASSED. DDR_bin predicts overall survival (p=0.013) even though it did not discriminate platinum response labels (AUROC=0.517). This is publication-grade evidence for prognostic value.",
  "manuscript_claim": "DDR_bin predicted overall survival with HR = 0.62 (95% CI: 0.42-0.90, p = 0.013). Patients with high DDR_bin had median OS of 68.9 vs 51.0 months (\u0394 = 17.9 months)."
}